CGTN: China’s COVID-19 vaccines proven safe, effective by trials and data


Clinical studies and real-world data have demonstrated the safety and efficacy of COVID-19 vaccines made in China. People in China and other countries have been saved thanks to the vaccines; this is an unquestionable success that cannot be disputed by denialists.

Numerous choices

  • The only country with COVID-19 vaccines that were generated using several technical avenues and function in various ways is China.
  • In addition to the cutting-edge mRNA vaccines produced by Pfizer Inc., individuals can also select the tried-and-true conventional inactivated vaccines that are widely used in China.
  • To provide individuals more choices, Chinese companies have produced protein subunit vaccinations and viral vector vaccines.
  • Chinese vaccinations are available in a variety of formats, including injections, inhalers, and nasal sprays, depending on your preference.
  • There are now 13 different vaccines on the market in China.

Safety first

“China always puts first the safety of vaccines”, “China-made vaccines have a good safety record with overall low adverse event rate.”

Wang Wenbin, spokesperson of the Ministry of Foreign Affairs, at a regular press conference on Friday

The fact that billions of people have received the Chinese vaccinations is unmistakable proof of the vaccines’ safety. As of January 12, more than 1.3 billion people—including more than 241 million adults over the age of 60—had received more than 3.4 billion doses of vaccinations in China.

The Chinese Center for Disease Control and Prevention (CDC) reports that between December 15, 2020, and April 30, 2021, 265 million doses of the COVID-19 vaccination were provided on the Chinese mainland, with a rate of 0.07 per 100,000 doses, and 188 cases of serious adverse reactions were reported. The CDC referred to the rate as “very unusual.”

Three Chinese vaccines are listed on the World Health Organization’s Emergency Use List (WHO). The only vaccination on the list that is suggested for use on kids between the ages of three and four is Sinovac’s CoronaVac. The use of CoronaVac on six-month-old infants was authorised by Chilean and Chinese regulators in August 2022.

Dependable efficiency

According to Chinese law, a vaccination must undergo clinical trials to receive government approval, during which the efficacy must be established through research. Numerous Chinese vaccinations, including those made by Sinopharm and Sinovac, have been tested on individuals of various racial backgrounds.

Two doses of the CoronaVac vaccine had an effectiveness of 83.5% in a Phase-III trial in Turkey including more than 10,000 participants. The vaccine “has high efficacy with a decent safety and tolerability profile,” according to researchers.

A significant multi-country Phase-III trial of Sinopharm’s vaccine, according to the WHO, also showed a 79 percent efficacy against hospitalisation, which is high enough to receive the organization’s recommendation.

Tedros Adhanom Ghebreyesus, the head of the WHO, stated that the agency included the first Chinese vaccine for emergency use because of its “safety, efficacy, and quality.”

The inactive vaccine from China had an advantage over other vaccines produced at the time by Moderna and Pfizer: it could be shipped and stored in a typical refrigerator at 2 to 8 degrees Celsius. Large quantities of vaccinations may be kept at low temperatures and are especially well suited for underdeveloped nations with insufficient transportation and vaccine storage facilities.

Assisting the globe

China fulfilled its worldwide obligation by giving and exporting a significant number of its COVID-19 vaccinations, especially at a time when some of the most industrialized nations were stockpiling the vaccines for their own populations.

By the end of March 2021, the US and UK would have essentially no vaccine storage left to export, according to data analytics company Airfinity. France’s president, Emmanuel Macron, a close ally of the United States, asked the country to lift its ban on the export of COVID-19 vaccines and ingredients in May 2021, after more than half of Americans have gotten at least one dose.

More than 2.2 billion vaccine doses produced in China were sent to more than 120 nations and international organisations. Chinese vaccines were utilised by people in more than 100 countries, including presidents of more than 30 nations.

The Chinese immunizations are prized successes in the nation’s fight against COVID-19, which helped people in numerous other nations as well. It is not appropriate to discount or misrepresent these contributions.

Next Post

Merck Selects Perceiv AI for Inaugural Digital Sciences Studio Cohort

Perceiv AI declared that Merck had chosen it and eight other early-stage biomedical businesses from a pool of 152 applications for the first cohort of the Merck Digital Sciences Studio (MDSS). The program was launched in November to support cutting-edge digital technology for drug research. “Being selected for the Merck […]
Perceiv AI